FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004137182> ?p ?o ?g. }

• W2004137182 endingPage "51957" @default.
• W2004137182 startingPage "51953" @default.
• W2004137182 abstract "During infection, bacterial pathogens utilize a type III secretion system to inject effectors into the cytoplasm of a target cell where they disrupt the defense system of the host cell. Vibrio parahaemolyticus, a causative agent of gastroenteritis endemic in Southeast Asia, has a type III secretion system that encodes a novel member of the YopJ-like protein effector family, VopA (Vibrioouter protein A). Our studies revealed that Vibrio VopA encodes an evolutionarily conserved activity that is extremely potent and requires an intact catalytic site to abrogate signaling pathways in a manner distinct from that of other YopJ-like effectors. We observed that VopA efficiently inhibits the MAPK signaling pathways but not the NFκB pathway in mammalian cells. When expressed in yeast, VopA induces a growth arrest phenotype and also blocks yeast MAPK signaling pathways. Our observations provide insight into the immense diversity of targets utilized by YopJ-like effectors to manipulate eukaryotic signaling machineries that are important for the response and survival of the host cell during infection and/or symbiosis. During infection, bacterial pathogens utilize a type III secretion system to inject effectors into the cytoplasm of a target cell where they disrupt the defense system of the host cell. Vibrio parahaemolyticus, a causative agent of gastroenteritis endemic in Southeast Asia, has a type III secretion system that encodes a novel member of the YopJ-like protein effector family, VopA (Vibrioouter protein A). Our studies revealed that Vibrio VopA encodes an evolutionarily conserved activity that is extremely potent and requires an intact catalytic site to abrogate signaling pathways in a manner distinct from that of other YopJ-like effectors. We observed that VopA efficiently inhibits the MAPK signaling pathways but not the NFκB pathway in mammalian cells. When expressed in yeast, VopA induces a growth arrest phenotype and also blocks yeast MAPK signaling pathways. Our observations provide insight into the immense diversity of targets utilized by YopJ-like effectors to manipulate eukaryotic signaling machineries that are important for the response and survival of the host cell during infection and/or symbiosis. The Gram-negative marine bacterium Vibrio parahaemolyticus is a major agent responsible for gastroenteritis outbreaks associated with the consumption of infected seafood (1McCarter L. J. Mol. Microbiol. Biotechnol. 1999; 1: 51-57PubMed Google Scholar). Areas of recent outbreaks range from the coastal regions of North America to Eastern Asia. The bacterial pathogen Yersinia pestis is the causal agent for the bubonic plague, whereas Yersinia pseudotuberculosis and Yersinia enterocolitica are causal agents for gastrointestinal disorders (2Cornelis G.R. J. Cell Biol. 2002; 158: 401-408Crossref PubMed Scopus (321) Google Scholar). Salmonella typhimurium is a facultative intracellular pathogen that causes gastroenteritis, and because it is carried by a variety of animal hosts, it is of increasing concern to the food industry in the developed world (3Prager R. Rabsch W. Streckel W. Voigt W. Tietze E. Tschape H. J. Clin. Microbiol. 2003; 41: 4270-4278Crossref PubMed Scopus (66) Google Scholar). All three pathogens harbor pathogenicity islands that encode a type III secretion system, which is used to inject effector proteins into the host cytoplasm. Effector proteins are molecules that mimic a eukaryotic activity and are used by pathogens to disrupt signaling in the infected cell. All three of the aforementioned bacterial pathogens encode an effector protein that belongs to the family of YopJ-like proteins. YopJ, the founding member of this family, is an effector protein expressed by Yersinia spp. that is able to block the innate immune response in infected target cells (4Orth K. Curr. Opin. Microbiol. 2002; 5: 38-43Crossref PubMed Scopus (156) Google Scholar). Expression of cytokines and anti-apoptotic factors are prevented during a Yersinia infection because YopJ is able to inhibit MAPK 1The abbreviations used are: MAPK, mitogen-activated protein kinase; HA, hemagglutinin; ERK, extracellular signal-regulated kinase; TNF, tumor necrosis factor; HOG, high osmolarity growth. signaling pathways and the NFκB pathway by preventing the activation of the superfamily of MAPK kinases (5Orth K. Palmer L.E. Bao Z.Q. Stewart S. Rudolph A.E. Bliska J.B. Dixon J.E. Science. 1999; 285: 1920-1923Crossref PubMed Scopus (322) Google Scholar). Later studies demonstrated that the family of YopJ-like proteins encodes a cysteine protease domain and that the wild type but not the catalytically inactive forms are able to inhibit signaling pathways (6Orth K. Xu Z. Mudgett M.B. Bao Z.Q. Palmer L.E. Bliska J.B. Mangel W.F. Staskawicz B. Dixon J.E. Science. 2000; 290: 1594-1597Crossref PubMed Scopus (437) Google Scholar). The family of YopJ-like proteins is found in a wide variety of animal and plant pathogens as well as the plant symbiont Rhizobium (4Orth K. Curr. Opin. Microbiol. 2002; 5: 38-43Crossref PubMed Scopus (156) Google Scholar, 7Staskawicz B.J. Mudgett M.B. Dangl J.L. Galan J.E. Science. 2001; 292: 2285-2289Crossref PubMed Scopus (278) Google Scholar). The effector AvrA from S. typhimurium is the only other YopJ-like protein from an animal pathogen studied to date and is implicated in the inhibition of the NFκB pathway (8Collier-Hyams L.S. Zeng H. Sun J. Tomlinson A.D. Bao Z.Q. Chen H. Madara J.L. Orth K. Neish A.S. J. Immunol. 2002; 169: 2846-2850Crossref PubMed Google Scholar). V. parahaemolyticus is phylogenetically close to Vibrio cholerae (the causative agent of cholera), and recent sequencing of the V. parahaemolyticus genome reveals the existence of two pathogenicity islands (PAI and PAII), which are not found in V. cholerae (9Makino K. Oshima K. Kurokawa K. Yokoyama K. Uda T. Tagomori K. Iijima Y. Najima M. Nakano M. Yamashita A. Kubota Y. Kimura S. Yasunaga T. Honda T. Shinagawa H. Hattori M. Iida T. Lancet. 2003; 361: 743-749Abstract Full Text Full Text PDF PubMed Scopus (776) Google Scholar). Encoded within PAII is a type III secretion system and an effector protein, referred to as VopA, sharing ∼55% similarity with the YopJ-like proteins from Yersinia and Salmonella (9Makino K. Oshima K. Kurokawa K. Yokoyama K. Uda T. Tagomori K. Iijima Y. Najima M. Nakano M. Yamashita A. Kubota Y. Kimura S. Yasunaga T. Honda T. Shinagawa H. Hattori M. Iida T. Lancet. 2003; 361: 743-749Abstract Full Text Full Text PDF PubMed Scopus (776) Google Scholar). V. parahaemolyticus is a bacteria that is associated with two hosts: shellfish and human. Within shellfish, it exists as a commensal, whereas in humans, it is an incidental pathogen (acquired by eating contaminated shellfish). YopJ-like effectors are expressed by a number of bacteria, including pathogens, commensals, and symbionts. These effector proteins, like other type III secreted virulence factors, are expressed by the bacteria and injected into the target host cell where they manipulate the host machinery. Our studies reveal that VopA, encoded by V. parahaemolyticus, is able to manipulate eukaryotic signaling machineries, and this may be of use during its existence as a commensal or incidental pathogen. Herein, we observe that VopA functions in a mechanistically similar manner to other YopJ-like proteins but demonstrates a remarkable diversity in its inhibitory profile of signaling pathways. Cloning of Effectors—VopA was amplified by PCR from V. parahaemolyticus genomic DNA with a 5′-HindIII primer and a 3′-FLAG-stop-ApaI primer and cloned into the mammalian expression vector pSFFV. The VopA alanine mutant was generated by site-directed mutagenesis using the Stratagene QuikChange mutagenesis kit. VopA and VopA C167A were amplified by PCR using pSFFV VopA or pSFFV VopA C167A as template with 5′-EcoRI and 3′-FLAG-stop-XhoI primers and cloned into the yeast expression vector pRS413 under control of the GAL promoter. All constructs were confirmed by DNA sequencing. MAPK Assays—293T cells were transfected with or without a MAPK (HA-ERK; 100 ng) in the presence or absence of YopJ-like effector plasmids (100 ng). And after 48 h of growth, cells were starved for 3 h followed by treatment or no treatment with a stimulus (epidermal growth factor, 50 ng/ml). Cells lysates were analyzed by immunoblot analysis with rabbit anti-phospho-ERK antibody (Cell Signaling Technology, Inc.) and mouse anti-HA antibody (Babco). YopJ-like effectors were detected using mouse anti-FLAG antibody (Sigma). NFκB Assays—293T and HeLa cells were transfected with or without FLAG-IκB (1 μg) in the presence or absence of YopJ-like effector plasmids (50 ng). After 36 h of growth, 293T cells were treated with TNFα (50 ng/ml) for 30 min, and HeLa cells were treated with interleukin-1β (10 ng/ml) for 15 min. Cell lysates were analyzed by immunoblot analysis with rabbit anti-phospho-IκB antibody (Cell Signaling Technology, Inc) and mouse anti-FLAG antibody (Sigma). Death Assays—Jurkat cells were transiently transfected using a BTX ECM electroporator (260 V, 1050 microfarads, 720 ohms) with 10 μg of each plasmid and 2 μg of pMEM-YFP membrane-bound yellow fluorescent protein (Clontech) as a transfection marker. Twenty-four hours later, cells were left untreated or treated with 100 ng/ml human TNFα for ∼18 h. Death was assessed by flow cytometric analysis of annexin V-activated protein C binding and propidium iodide. Live cell percentages were calculated as the percentage of yellow fluorescent protein-positive cells that were annexin V and propidium iodide negative. Specific cell death was calculated using the formula 100 × (1– TNF treated/untreated) for the live cell percentages in each condition. Yeast Growth and MAPK Assays—Yeast cells expressing the indicated empty vector or the YopJ-like effector plasmids were assayed for growth by plating on glucose media, galactose media, or galactose media containing 1 m sorbitol. For growth curves, overnight cultures grown in glucose were diluted back to an OD of 0.1 in 20 ml of indicated media, and the absorbance was measured at 600 nm. For MAPK assays, yeast cells containing either an empty vector or YopJ, YopJ C/A, VopA, or VopA C/A vectors under control of the galactose promoter were grown to mid-log phase in glucose media and then shifted to galactose media to induce protein expression for 3 h. Cells were then induced with either 0.7 m sorbitol for 2.5 min or 12 mm caffeine for 1 h. Protein extract from these cells were isolated as described in Yoon et al. (10Yoon S. Liu Z. Eyobo Y. Orth K. J. Biol. Chem. 2003; 278: 2131-2135Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar) and analyzed by immunoblotting with anti-phospho-p38 antibody (Cell Signaling Technology, Inc.) or anti-phospho-p44/42 MAPK antibody (Cell Signaling Technology, Inc.), anti-FLAG antibody, and anti-porin antibody (loading control). Accession Numbers—The GenBank™ accession number for YopJ is AY606230 and for VopA is AY597337. Lack of Inhibition of NFκB Pathway by VopA—We examined whether Vibrio VopA is able to inhibit the induction of innate immune response by blocking the NFκB pathway in a manner similar to other YopJ-like effector proteins (5Orth K. Palmer L.E. Bao Z.Q. Stewart S. Rudolph A.E. Bliska J.B. Dixon J.E. Science. 1999; 285: 1920-1923Crossref PubMed Scopus (322) Google Scholar, 8Collier-Hyams L.S. Zeng H. Sun J. Tomlinson A.D. Bao Z.Q. Chen H. Madara J.L. Orth K. Neish A.S. J. Immunol. 2002; 169: 2846-2850Crossref PubMed Google Scholar). Wild-type YopJ and VopA and the catalytically inactive forms of these effectors (YopJC172A or VopAC167A) along with FLAG-tagged IκB were transfected into 293T cells or HeLa cells and then stimulated with either TNFα or interleukin-1β, respectively. Surprisingly, VopA demonstrated no inhibitory activity on the NFκB signaling pathway. Neither wild-type VopA nor the catalytically inactive VopAC167A are able to inhibit the phosphorylation of IκB with either stimulus (TNFα or interleukin-1β) (Fig. 1, A and B, respectively). In NFκB luciferase reporter assays, VopA is unable to inhibit TNFα-induced activity. 2M. Roberts and R. M. Siegel, unpublished observations. Taken together, these observations support the hypothesis that VopA has no effect on the NFκB pathway, which is in contrast to the two other YopJ-like effectors from animal pathogens, YopJ and AvrA. VopA Inhibits the Mammalian MAPK Pathways—Yersinia YopJ is able to inhibit MAPK signaling pathways, so we next assessed the ability of Vibrio VopA to inhibit the mammalian MAPK pathways. 293T cells were transfected with various YopJ-like effectors in the presence of HA-ERK followed by treatment with epidermal growth factor (5Orth K. Palmer L.E. Bao Z.Q. Stewart S. Rudolph A.E. Bliska J.B. Dixon J.E. Science. 1999; 285: 1920-1923Crossref PubMed Scopus (322) Google Scholar). Both wild-type YopJ and VopA, but not the catalytically inactive forms of these effectors (YopJC172A or VopAC167A), are able to inhibit extracellular growth factor-induced ERK activation (Fig. 2A). In a similar fashion, both YopJ and VopA are able to inhibit the other MAPK pathways. 3J. E. Trosky and K. Orth, unpublished observations. These studies provide the first evidence that Vibrio VopA is able to inhibit mammalian signaling pathways. However, the various YopJ-like effectors appear to target distinct sets of signaling pathways within the eukaryotic cell, because in contrast to YopJ, no interaction is observed between VopA and the family of MAPK kinases in yeast two-hybrid binding assays. 3J. E. Trosky and K. Orth, unpublished observations. Both YopJ and VopA are very efficient at inhibiting the MAPK pathways, but detecting the expression of these YopJ-like proteins is extremely difficult (Fig. 2A). To determine the potency of inhibition by these effectors, we analyzed their MAPK inhibitory activity over a range of expression conditions. Inhibition of the MAPK signaling pathway is observed with as little as 1 ng of YopJ- or VopA-transfected DNA. Although the inhibition of the MAPK pathways is comparable between the two effectors, the amount of YopJ-FLAG protein appears to be at least 10-fold greater than that of VopA-FLAG (as detected by anti-FLAG immunoblots) (Fig. 2B). The Role of VopA in Programmed Cell Death—Having established a profile of inhibitory activity for these YopJ-like effectors, we wanted to investigate what role these effectors (independent of other pathogenic factors) play on the fate of an infected cell. We utilized the well established system in lymphoma cells whereby TNFα-induced apoptosis is prevented by the induction of the NFκB pathway resulting in the expression of anti-apoptotic factors (11Beg A.A. Baltimore D. Science. 1996; 274: 782-784Crossref PubMed Scopus (2935) Google Scholar, 12Van Antwerp D.J. Martin S.J. Kafri T. Green D.R. Verma I.M. Science. 1996; 274: 787-789Crossref PubMed Scopus (2449) Google Scholar, 13, Deleted in proofGoogle Scholar). Effectors were transfected into Jurkat cells and following stimulation with TNFα, were assessed for survival (Fig. 3). Cell death was not observed in control cells in the presence or absence of stimulus. Wild-type YopJ, but not the catalytically inactive form of YopJ, is able to efficiently promote cell death in Jurkat cells but only in the presence of stimulus, which supports the hypothesis that the Yersinia YopJ effector does not directly activate death machinery but promotes cell death by the blocking of signaling pathways. The ability of VopA to promote cell death in the presence of stimulus is marginal (Fig. 3) and cannot be attributed to blocking the NFκB pathway but may result as an indirect consequence of its extremely potent inhibition of the MAPK pathways. Expression of VopA in Yeast Causes a Growth Arrest Phenotype—One of the characteristics of bacterial pathogenic effectors secreted by a type III secretion system is that their usurped eukaryotic activities are evolutionarily conserved. Studies with Saccharomyces cerevisiae expressing a galactose-inducible YopJ plasmid demonstrated that the mechanism used by YopJ to inhibit the MAPK signaling pathways is evolutionarily conserved (10Yoon S. Liu Z. Eyobo Y. Orth K. J. Biol. Chem. 2003; 278: 2131-2135Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). To initially test the effect that VopA has on the MAPK pathways in yeast, strains containing this effector and its mutant counterpart, under the control of a galactose-inducible promoter, were grown to mid-log phase in glucose media followed by plating onto glucose or galactose media. When yeast cells containing VopA plasmid are plated on galactose, thereby inducing the expression of VopA, the yeast cells are unable to grow (Fig. 4D). In contrast, yeast cells expressing the catalytically inactive VopAC167A are able to grow on galactose media. Yeast cells expressing VopA when scraped off the galactose plates are able to recover and grow when plated on glucose plates, supporting the idea that the catalytic activity of the Vibrio effector, VopA, induces a growth arrest phenotype (data not shown). Using liquid growth culture studies, we observed the effects on the growth of yeast cells expressing various forms of YopJ-like proteins. Yeast cells containing a control vector or vector expressing YopJ, YopJ C172A, or VopA C167A grow at approximately the same rate (Fig. 4B). In contrast, the growth of VopA-expressing yeast cells is dramatically hindered, but they continue to grow, albeit at a slower rate than the other strains (Fig. 4B). In cells expressing VopA, growth arrest is observed over an extended period of time, indicating that the growth arrest is not likely to be a cell cycle-dependent defect. The phenotype is dependent on wild-type VopA and not the catalytically inactive form of VopA, indicating that the mechanism of inhibition is similar to other YopJ-like effectors but that the targets are distinct. Inhibition of MAPK Pathways by VopA Is Evolutionarily Conserved—To investigate whether VopA, like YopJ, inhibits MAPK signaling pathways in yeast, cells containing the various effectors were plated on galactose media with 1 m sorbitol, which results in the activation the high osmolarity growth (HOG) MAPK pathway (10Yoon S. Liu Z. Eyobo Y. Orth K. J. Biol. Chem. 2003; 278: 2131-2135Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). As expected, yeast expressing either YopJ or VopA, but not the catalytically inactive mutants, plated on galactose media containing 1 m sorbitol are unable to grow (Fig. 4D). Consistent with our observations in mammalian systems, Salmonella AvrA shows no obvious inhibitory affect on the MAPK pathways in yeast (data not shown). When yeast expressing YopJ or VopA are grown in liquid media containing 1 m sorbitol, the growth phenotype is quite striking (Fig. 4C). Growth is almost immediately arrested in the presence of VopA, whereas in the presence of YopJ, the growth arrest requires more time. These observations further emphasize the difference in targets between YopJ and VopA and indicate that the growth arrest phenotype in the presence of VopA does not depend only on the inhibition of the activated HOG MAPK pathway. To test the ability of VopA to inhibit the HOG MAPK pathway, yeast cells were grown in glucose media to mid-log phase and then transferred to galactose media to induce expression of the YopJ-like proteins. These cells were incubated with sorbitol, and the lysates of cells were analyzed for induction of the HOG MAPK pathway (10Yoon S. Liu Z. Eyobo Y. Orth K. J. Biol. Chem. 2003; 278: 2131-2135Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Yeast cells containing either a control vector or the plasmids encoding catalytically inactive forms of YopJ or VopA are able to activate Hog1p via phosphorylation, whereas wild-type YopJ and VopA inhibit Hog1p activation (Fig. 5A). Similar results are observed using caffeine to induce the cell wall integrity MAPK pathway (14Akeda Y. Kodama T. Kashimoto T. Cantarelli V. Horiguchi Y. Nagayama K. Iida T. Honda T. Infect. Immun. 2002; 70: 970-973Crossref PubMed Scopus (20) Google Scholar); yeast cells expressing wild-type YopJ or VopA, but not their mutant counterparts, are unable to induce the activation of Mpk1p via phosphorylation in this pathway (Fig. 5B). VopA, like YopJ, inhibits evolutionarily conserved MAPK signaling pathways in yeast, but unlike YopJ, demonstrates the ability to induce a growth arrest phenotype in yeast indicating a distinct set of targets for VopA. The profiles of inhibition for each of the mammalian YopJ-like effectors are clearly distinct. VopA potently blocks the evolutionarily conserved MAPK pathways, YopJ blocks MAPK pathways and the NFκB pathway (5Orth K. Palmer L.E. Bao Z.Q. Stewart S. Rudolph A.E. Bliska J.B. Dixon J.E. Science. 1999; 285: 1920-1923Crossref PubMed Scopus (322) Google Scholar), and AvrA blocks only the NFκB pathway (8Collier-Hyams L.S. Zeng H. Sun J. Tomlinson A.D. Bao Z.Q. Chen H. Madara J.L. Orth K. Neish A.S. J. Immunol. 2002; 169: 2846-2850Crossref PubMed Google Scholar) (Fig. 6A). Each pathogen has evolved to encode a YopJ-like effector displaying a unique inhibitory activity that requires a common catalytic site (Fig. 6B) that benefits its respective pathogen in different ways. The activity of Yersinia YopJ complements its fellow effectors by blocking the production of cytokines and anti-apoptotic machinery, thereby preventing the induction of the innate immune response and promoting apoptosis. Salmonella AvrA does not affect MAPK signaling in mammalian cells or yeast3 but does inhibit the NFκB pathway (8Collier-Hyams L.S. Zeng H. Sun J. Tomlinson A.D. Bao Z.Q. Chen H. Madara J.L. Orth K. Neish A.S. J. Immunol. 2002; 169: 2846-2850Crossref PubMed Google Scholar), albeit weakly, and does abrogate the constitutive degradation of β-catenin (15Sun J. Hobert M.E. Rao A.S. Neish A.S. Madara J.L. Am. J. Physiol. 2004; 287: G220-G227Crossref PubMed Scopus (93) Google Scholar). This inhibitory activity results in c-Myc-induced proliferation of the infected cell, which may prolong the life of the infected cell and allow for propagation of an intracellular pathogen (15Sun J. Hobert M.E. Rao A.S. Neish A.S. Madara J.L. Am. J. Physiol. 2004; 287: G220-G227Crossref PubMed Scopus (93) Google Scholar). Vibrio VopA, which we have shown to be an extremely potent inhibitor of the evolutionarily conserved MAPK pathways, may function to inhibit cytokine production resulting in attenuation of the host defense response. The activity of VopA along with other virulence factors could facilitate colonization in the intestine of humans resulting in propagation of the pathogen. Alternatively, VopA may by used to attenuate signaling while existing as a commensal in the shellfish host. Currently, only laborious animal models (e.g. the ligated rabbit ileal loop model) exist for studying V. parahaemolyticus (16Nishibuchi M. Kaper J.B. Infect. Immun. 1995; 63: 2093-2099Crossref PubMed Google Scholar), but systems to study infection by V. parahaemolyticus using a tissue culture-based approach are currently being developed. 4J. E. Trosky, L. McCarter, and K. Orth, unpublished observations. In summary, three different types of intestinal pathogens have usurped a structurally conserved and mechanistically similar activity in the form of a YopJ-like effector. Recent studies suggest that this activity was originally captured by the plant bacterial pathogen, Xanthomonas, which expresses not only YopJ-like effectors (encoding remote similarity to a ubiquitin-like protein protease (Ulp1)) but also the effector XopD (a member of the Ulp1 protein family) (4Orth K. Curr. Opin. Microbiol. 2002; 5: 38-43Crossref PubMed Scopus (156) Google Scholar, 17Hotson A. Chosed R. Shu H. Orth K. Mudgett M.B. Mol. Microbiol. 2003; 50: 377-389Crossref PubMed Scopus (219) Google Scholar). XopD is a constitutively active enzyme with plant-specific deSUMOylating enzyme activity (17Hotson A. Chosed R. Shu H. Orth K. Mudgett M.B. Mol. Microbiol. 2003; 50: 377-389Crossref PubMed Scopus (219) Google Scholar). These observations support a hypothesis that pathogenic bacteria have usurped the Ulp1 hydrolase activity. The catalytic domain of this molecule may then have been transformed into a unique activity that is maintained and used by a specific pathogen for targeting and inhibiting a distinct set of signaling pathways for the advantage of the pathogen during infection of the host. As YopJ effectors are maintained and expressed by both plant and animal pathogens as well as a plant symbiont (and most likely in yet to be discovered animal commensals), they provide powerful tools for identifying critical steps in eukaryotic signaling machineries that are important for host response and survival during infection and/or symbiosis. We thank Meg Phillips, Zhengchang Liu, Lora Hooper, Vanessa Sperandio, and Ron Taussig for critical analysis and helpful suggestions during the preparation of this manuscript. We are grateful for the expert assistance from Alisha Tizenor with figures and N. V. Grishin with bioinformatics. We thank Renee Chosed, Yong Wang, Yvonne Eyobo, Andrew Neish, James Z. Chen, and Chee Kwee Ea for technical support and reagents." @default.
• W2004137182 created "2016-06-24" @default.
• W2004137182 creator A5002789696 @default.
• W2004137182 creator A5011873377 @default.
• W2004137182 creator A5022663310 @default.
• W2004137182 creator A5026965478 @default.
• W2004137182 creator A5042319637 @default.
• W2004137182 creator A5052782883 @default.
• W2004137182 creator A5084864678 @default.
• W2004137182 date "2004-12-01" @default.
• W2004137182 modified "2023-10-13" @default.
• W2004137182 title "Inhibition of MAPK Signaling Pathways by VopA from Vibrio parahaemolyticus" @default.
• W2004137182 cites W1492606093 @default.
• W2004137182 cites W1624615502 @default.
• W2004137182 cites W1888783223 @default.
• W2004137182 cites W1965970815 @default.
• W2004137182 cites W1974405307 @default.
• W2004137182 cites W2030598858 @default.
• W2004137182 cites W2054479383 @default.
• W2004137182 cites W2057886904 @default.
• W2004137182 cites W2122471134 @default.
• W2004137182 cites W2125090285 @default.
• W2004137182 cites W2132916034 @default.
• W2004137182 cites W2140363516 @default.
• W2004137182 cites W2154496121 @default.
• W2004137182 cites W2170706669 @default.
• W2004137182 doi "https://doi.org/10.1074/jbc.m407001200" @default.
• W2004137182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15459200" @default.
• W2004137182 hasPublicationYear "2004" @default.
• W2004137182 type Work @default.
• W2004137182 sameAs 2004137182 @default.
• W2004137182 citedByCount "116" @default.
• W2004137182 countsByYear W20041371822012 @default.
• W2004137182 countsByYear W20041371822013 @default.
• W2004137182 countsByYear W20041371822014 @default.
• W2004137182 countsByYear W20041371822015 @default.
• W2004137182 countsByYear W20041371822016 @default.
• W2004137182 countsByYear W20041371822017 @default.
• W2004137182 countsByYear W20041371822018 @default.
• W2004137182 countsByYear W20041371822019 @default.
• W2004137182 countsByYear W20041371822020 @default.
• W2004137182 countsByYear W20041371822021 @default.
• W2004137182 countsByYear W20041371822022 @default.
• W2004137182 countsByYear W20041371822023 @default.
• W2004137182 crossrefType "journal-article" @default.
• W2004137182 hasAuthorship W2004137182A5002789696 @default.
• W2004137182 hasAuthorship W2004137182A5011873377 @default.
• W2004137182 hasAuthorship W2004137182A5022663310 @default.
• W2004137182 hasAuthorship W2004137182A5026965478 @default.
• W2004137182 hasAuthorship W2004137182A5042319637 @default.
• W2004137182 hasAuthorship W2004137182A5052782883 @default.
• W2004137182 hasAuthorship W2004137182A5084864678 @default.
• W2004137182 hasBestOaLocation W20041371821 @default.
• W2004137182 hasConcept C185592680 @default.
• W2004137182 hasConcept C2776154503 @default.
• W2004137182 hasConcept C2776575720 @default.
• W2004137182 hasConcept C523546767 @default.
• W2004137182 hasConcept C54355233 @default.
• W2004137182 hasConcept C57074206 @default.
• W2004137182 hasConcept C62478195 @default.
• W2004137182 hasConcept C86803240 @default.
• W2004137182 hasConcept C89423630 @default.
• W2004137182 hasConcept C95444343 @default.
• W2004137182 hasConceptScore W2004137182C185592680 @default.
• W2004137182 hasConceptScore W2004137182C2776154503 @default.
• W2004137182 hasConceptScore W2004137182C2776575720 @default.
• W2004137182 hasConceptScore W2004137182C523546767 @default.
• W2004137182 hasConceptScore W2004137182C54355233 @default.
• W2004137182 hasConceptScore W2004137182C57074206 @default.
• W2004137182 hasConceptScore W2004137182C62478195 @default.
• W2004137182 hasConceptScore W2004137182C86803240 @default.
• W2004137182 hasConceptScore W2004137182C89423630 @default.
• W2004137182 hasConceptScore W2004137182C95444343 @default.
• W2004137182 hasIssue "50" @default.
• W2004137182 hasLocation W20041371821 @default.
• W2004137182 hasOpenAccess W2004137182 @default.
• W2004137182 hasPrimaryLocation W20041371821 @default.
• W2004137182 hasRelatedWork W2138808184 @default.
• W2004137182 hasRelatedWork W2184678326 @default.
• W2004137182 hasRelatedWork W2353187112 @default.
• W2004137182 hasRelatedWork W2378163614 @default.
• W2004137182 hasRelatedWork W2380387599 @default.
• W2004137182 hasRelatedWork W2386508772 @default.
• W2004137182 hasRelatedWork W2395683811 @default.
• W2004137182 hasRelatedWork W2409380104 @default.
• W2004137182 hasRelatedWork W3179743103 @default.
• W2004137182 hasRelatedWork W1483148221 @default.
• W2004137182 hasVolume "279" @default.
• W2004137182 isParatext "false" @default.
• W2004137182 isRetracted "false" @default.
• W2004137182 magId "2004137182" @default.
• W2004137182 workType "article" @default.